RxDoctor Payments Data

Rhondi Meiusi, MD

Ophthalmology · Edina, MNNPI 1437167848

Payments from drug & device makers

What this record shows

Alcon accounts for 78.9% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $2,273 and has fallen 80.4% since, to $445 in 2025.

$3,436in general payments, 2019–2025

Across 58 payments — averaging $59.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • Glaukos Corporation$186
  • Oyster Point Pharma, Inc.$126
  • Johnson & Johnson Surgical Vision, Inc.$71
  • Coopervision Inc.$60
  • Novartis$51
  • plus $231 from 10 others

What the payments were for

  • Food & beverage$1,50344%
  • Other$1,93356%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,436 in reported general payments places this provider in the 85th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$204,614
Medicare patients
779
Services billed
1,602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine26$45,770
XiidraLifitegrast21$26,262
LumiganBimatoprost32$20,153
Restasis MultidoseCyclosporine24$16,339
RhopressaNetarsudil Mesylate14$8,119
Cyclosporine17$7,912
VyzultaLatanoprostene Bunod13$7,354
Travoprost22$6,665
Latanoprost179$4,256
Timolol Maleate134$2,578
Tobramycin-DexamethasoneTobramycin/Dexamethasone28$1,704
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat40$996
Ketorolac Tromethamine59$847
Prednisolone Acetate21$836
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha12$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose$30$82,26182 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in Edina

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →